Navigation Links
Data on SEEK's Novel Immunotherapy for HIV Published in Virology Journal
Date:4/16/2013

LONDON, April 16, 2013 /PRNewswire/ --

 Antibody Treatment for HIV

SEEK, a privately-owned UK drug discovery group, announces that pre-clinical results on its HIV immunotherapy have been published in the peer-reviewed journal Virology Journal.  

SEEK's HIV immunotherapy triggers the immune system's cellular and antibody responses to selectively identify and kill HIV infected cells. The most exciting aspect of this therapy is that it directs the immune system towards short highly conserved regions of proteins produced by most circulating HIV strains. The triggered immune responses are highly effective both independently and in combination.

This opens up developing the antibody response into a monoclonal based therapy for treating HIV.

Monoclonal antibodies have revolutionised the treatment of cancer by improving outcomes and survival. In HIV/AIDS there is new interest in these products, as shown by the recent work of Duke University (USA) in developing a monoclonal antibody that prevents the virus from infecting cells. A monoclonal antibody capable of killing HIV-infected cells (potentially curative effect) would represent a radical new development in HIV therapy, which to this day relies on slowing down the virus rate of growth rather than in killing the cells that harbour it.  

By targeting a HIV component that is found only in infected cells and never in healthy cells, such monoclonal antibody therapy offers the potential of high specificity, reduced frequency of administration and minimal side-effects. This would represent a significant improvement over current anti-HIV drugs which require daily treatment and are associated with significant side effects.

Commenting on today's announcement, Gregory Stoloff , CEO of SEEK Group, said: "It is  very exciting to be at the forefront of this new approach which opens up HIV therapy to established and available antibody technology."

The manuscript: Olga Pleguezuelos, Gregory A Stoloff and Wilson Caparros-Wanderley , 'Synthetic immunotherapy induces HIV virus specific Th1 cytotoxic response and death of an HIV-1 infected human cell line through classic complement activation', Virology Journal 2013, 10:107, can be found at the following URL:  

http://www.virologyj.com/content/10/1/107

In July 2011, SEEK announced the results of a Phase Ib/II study in humans which demonstrated that HIV immunotherapy showed a one log (approx 90 percent) difference in viral count in HIV-infected people compared with the placebo group, after just a single administration.

About SEEK

Founded in 2004, SEEK (previously known as PepTcell) is privately-owned and funded, with headquarters in London, UK. SEEK brings safe and low costs medicines to the patients as quickly as possible. It does this by modifying existing medicines to improve their efficacy within current label, dose and regime, by changing the indication but keeping the dose and dosing regime the same or by creating a new medicine when the previous options are unavailable.

Additional information about SEEK is available on the Company's website located at http://www.seekacure.com

For more information please contact:

Gregory Stoloff , CEO, SEEK                  
Tel +44(0)20-7153-6570

M:Communications
Mary Clark / Amber Bielecka / Hollie Vile        
Tel +44(0)20-7920-2330
seek@mcomgroup.com


'/>"/>
SOURCE SEEK
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Searcy Denney Scarola Barnhart & Shipley PA Seeks Damages Caused by Recalled Product
2. American Academy of Pain Medicine Reacts to PROP Petition to the FDA that Seeks to Limit Pain Medications for Legitimate Noncancer Pain Sufferers
3. $1,000,000 Global B.R.A.I.N. Prize Seeks Applicants
4. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
5. Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Market
6. Upcoming Presentations on Global Market Access Issues and Trends in Health Economics and Outcomes Research at ISPOR 2012 by Novel Health Strategies
7. Scripps Doctors Study Novel New Device to Diagnose Irregular Heart Beat
8. Novelos Therapeutics Successfully Completes First Cohort In Phase 1b Solid Tumor Trial With I-131-CLR1404 (HOT) Cancer-Targeted Molecular Radiotherapeutic
9. Ambit Biosciences and Teva Announce Clearance of an Investigational New Drug (IND) Application for CEP-32496, A Novel BRAF(V600E) Inhibitor
10. New Data Support Role of Prometheus Laboratories Novel Assay in Optimizing IBD Treatment Management
11. Stiefel, a GSK company, enters agreement with Welichem Biotech, Inc. to acquire a novel topical agent for psoriasis and atopic dermatitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... HILDEN , Germany and ... QIAGEN N.V. (NASDAQ: QGEN ; Frankfurt ... into a licensing and co-development agreement with Therawis Diagnostics GmbH ... project will be to develop and market PITX2 as a ... and other high-risk breast cancer patients. "We are ...
(Date:5/25/2016)... YORK , May 25, 2016 ... Market Size, Share, Development, Growth and Demand Forecast to ... Syringe, Insulin Pump and Others)" published by P&S Market ... at $9,998.3 million in 2015, and it is expected ... Based on type, the insulin pump segment is expected ...
(Date:5/25/2016)... Digital Health Dialog, LLC dba EngagedMedia ... US Patent and Trademark Office of U.S. Patent ... for electronic opt-­in and processing of discount coupons ... compliance and otherwise. Logo - http://photos.prnewswire.com/prnh/20160524/371583LOGO ... "Our technology allows for individuals to opt­-in to ...
Breaking Medicine Technology:
(Date:5/25/2016)... ... May 25, 2016 , ... ... Heart Association/American Stroke Association's Get With The Guidelines®-Stroke Gold Plus Achievement Award ... a second for Memorial Healthcare System, recognizes its commitment to emergency stroke ...
(Date:5/25/2016)... , ... May 25, 2016 , ... The Georgia State ... of Excellence from the Atlanta Urban Design Commission. , The annual award recognizes projects, ... of Atlanta’s built environment, the preservation of its physical heritage and the balance between ...
(Date:5/25/2016)... ... May 25, 2016 , ... A new update to ... to motion capture, all by utilizing a common Wi-Fi network and a mobile device. ... data from any location with Wi-Fi, and use a mobile device to control the ...
(Date:5/25/2016)... ... May 25, 2016 , ... One Florida-based plastic surgeon’s enthusiasm is ... an article published May 13th on Vanity Fair. In fact, as the ... of their procedures broadcast to more than 800,000 Snapchat fans. Commenting on this trend, ...
(Date:5/25/2016)... , ... May 25, 2016 , ... The Bank of ... Biomedical Technology Program to help provide veterans a pathway to employment and successful careers ... a $20,000 check to Nick Hallack, President and CEO of Medisend, parent organization and ...
Breaking Medicine News(10 mins):